A phase Ib study of Durvalumab in combination with carbon-ion radiotherapy and weekly cisplatin for patients with locally advanced cervical cancer. An additional study for immunological prognostic factors
Not Applicable
- Conditions
- Cervical cancer
- Registration Number
- JPRN-UMIN000044470
- Lead Sponsor
- ational Institutes for Quantum and Radiological Science and Technology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- Female
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who are judged by the investigator or other physician to be unsuitable for participation in this study, such as those who are unlikely to comply with study procedures, restrictions, or requirements.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method